Recently, Chengdu Hyperway Pharmaceutical Co., Ltd. (hereinafter referred to as "Hyperway"), an enterprise in Tianfu Life Science Park, has once again won capital support with its strength and successfully completed the A+ round financing of nearly RMB 100 million.

      This round of financing was led by InnoPinnacle Fund and followed by three investment institutions: Orinno Capital, Guoyuan Innovation Investment, and Sunbow Capital. Under the current tight financing environment, this fully reflects the high recognition of the capital market for Hyperway's R&D strength and development potential.

        The funds raised in this round of financing will be mainly used for the clinical study of Hyperway's three innovative drugs HBW-3220, HBW-3210, and HBW-004285, and the promotion of multiple preclinical innovative drug R&D pipelines, so as to accelerate the development process of the company's innovative drugs from laboratory to clinical trials and from clinical trials to the market.

       
         The relevant person in charge of Orinno Capital said:

      Hyperway boasts fast R&D speed and high-quality achievements. It has laid out more than ten innovative drug R&D pipelines, focusing on multiple hot fields such as tumors, pain, and central nervous system diseases, and built a differentiated brain-penetrant drug development platform. As a local enterprise in CDHT, its continuous development and expansion hold significant industrial value for CDHT and even Chengdu. It is of great significance to building industrial ecosystems, strengthening key industrial chains, and industrial upgrading in CDHT. After the investment in Hyperway by Orinno Capital, both parties will deepen cooperation, match resources, and jointly contribute to the high-quality industrial development in CDHT.

        Wan Lei, Chairman and General Manager of Guoyuan Innovation Investment, said:

       Under the leadership of Dr. Li Yingfu, Hyperway has evolved into a robust and highly capable new drug research team. The company's core portfolio has made remarkable progress. In the context that new drug R&D enterprises are facing a tight financing environment, the team of Hyperway, with steadfast conviction and tireless dedication, continues to increase R&D investment, continuously develops new PCCs, and steadily promotes the clinical development process of projects such as those involving the third-generation BTK inhibitor and Nav1.8 inhibitor for pain relief. We firmly believe that Hyperway will seize the opportunity and accelerate its development in the next stage of innovative drug development!

       Wang Erlong, investment director of Sunbow Capital's medical and pharmaceutical sector, said:

       "Having real clinical value" is the fundamental motivation for us to invest in Hyperway. In the current sluggish market landscape in the pharmaceutical industry, only innovative drug companies with the potential to "address unmet clinical needs" will stand invincible. The clinical value of the third-generation BTK inhibitor, non-addictive Nav1.8 inhibitor, oral KRAS G12D inhibitor, and other pipelines currently promoted by Hyperway has been highly recognized by the industry and investors. Besides, Hyperway has gathered a top R&D team in the industry, laying a solid foundation for the smooth R&D of these pipelines. We believe that Hyperway has a bright future.

       Dr. Li Yingfu, Chairman of Hyperway, said:

      I'd like to appreciate the trust and support provided by the investment institutions to Hyperway. In the current severe and prudent investment and financing environment in both China and foreign countries, Hyperway still managed to complete the A+ round financing of nearly RMB 100 million, which is the greatest recognition of the company's prospects and R&D achievements. The team is greatly inspired by this. I'm especially grateful to InnoPinnacle Fund initiated by Innovent Biologics, a leading innovative drug manufacturer, for its initial investment as well as Orinno Capital, Guoyuan Innovation Investment, and Sunbow Capital for their follow-on investment. The successful completion of this round of financing will greatly accelerate the company's development and expedite the process of projects under research.

      Hyperway has always adhered to the enterprise goal of "Good Drugs Innovated in China", and is committed to creating original and world-class innovative drugs in China. In the past five years, all employees of Hyperway have united as one. With strong R&D strength and executive capability, multiple innovative drug projects have achieved outstanding results. In the future, Hyperway will stay true to its original aspiration, continue innovation, maintain high R&D efficiency, develop more internationally advanced innovative drugs, actively expand overseas markets, repay investors, and benefit patients around the world.